367 related articles for article (PubMed ID: 25985566)
1. Combination of oxaliplatin and S-1 versus sorafenib alone in patients with advanced hepatocellular carcinoma.
Lv Y; Liang R; Hu X; Liu Z; Liao X; Lin Y; Yuan C; Liao S; Li Q; Zhang J; Li Y
Pharmazie; 2014 Oct; 69(10):759-63. PubMed ID: 25985566
[TBL] [Abstract][Full Text] [Related]
2. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
Yoon EL; Yeon JE; Lee HJ; Suh SJ; Lee SJ; Kang SH; Kang K; Yoo YJ; Kim JH; Yim HJ; Byun KS
J Clin Gastroenterol; 2014 Mar; 48(3):e22-9. PubMed ID: 24045282
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma.
Lee DW; Lee KH; Kim HJ; Kim TY; Kim JS; Han SW; Oh DY; Kim JH; Im SA; Kim TY
BMC Cancer; 2018 Mar; 18(1):252. PubMed ID: 29506478
[TBL] [Abstract][Full Text] [Related]
4. S-1 plus sorafenib for the treatment of advanced hepatocellular carcinoma.
Huang W; You L; Liu D; Yang S; Liu M; Wang H; Wang P; Baikere P; Gu P; Abulikemu A; Yuan S; Fan X
J BUON; 2016; 21(6):1388-1393. PubMed ID: 28039697
[TBL] [Abstract][Full Text] [Related]
5. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
[TBL] [Abstract][Full Text] [Related]
6. A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma.
Ooka Y; Chiba T; Ogasawara S; Arai K; Suzuki E; Tawada A; Yamashita T; Kanai F; Kaneko S; Yokosuka O
Invest New Drugs; 2014 Aug; 32(4):723-8. PubMed ID: 24599799
[TBL] [Abstract][Full Text] [Related]
7. Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis.
He MK; Zou RH; Li QJ; Zhou ZG; Shen JX; Zhang YF; Yu ZS; Xu L; Shi M
Cardiovasc Intervent Radiol; 2018 May; 41(5):734-743. PubMed ID: 29327075
[TBL] [Abstract][Full Text] [Related]
8. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
9. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808
[TBL] [Abstract][Full Text] [Related]
10. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
Abou-Alfa GK; Johnson P; Knox JJ; Capanu M; Davidenko I; Lacava J; Leung T; Gansukh B; Saltz LB
JAMA; 2010 Nov; 304(19):2154-60. PubMed ID: 21081728
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
Kim GM; Jeung HC; Rha SY; Kim HS; Jung I; Nam BH; Lee KH; Chung HC
Eur J Cancer; 2012 Mar; 48(4):518-26. PubMed ID: 22243774
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
Miyaki D; Aikata H; Kan H; Fujino H; Urabe A; Masaki K; Fukuhara T; Kobayashi T; Naeshiro N; Nakahara T; Kawaoka T; Hiramatsu A; Takahashi S; Ishikawa M; Kakizawa H; Awai K; Chayama K
J Gastroenterol Hepatol; 2013 Dec; 28(12):1834-41. PubMed ID: 23808713
[TBL] [Abstract][Full Text] [Related]
14. A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer.
Takahara N; Isayama H; Nakai Y; Sasaki T; Hamada T; Uchino R; Mizuno S; Miyabayashi K; Kogure H; Yamamoto N; Sasahira N; Hirano K; Ijichi H; Tateishi K; Tada M; Koike K
Cancer Chemother Pharmacol; 2013 Nov; 72(5):985-90. PubMed ID: 23995699
[TBL] [Abstract][Full Text] [Related]
15. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study.
Liu Y; Yue H; Xu S; Wang F; Ma N; Li K; Qiao L; Wang J
Int J Clin Oncol; 2015 Oct; 20(5):952-9. PubMed ID: 25712158
[TBL] [Abstract][Full Text] [Related]
16. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G
Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.
Li J; Wang L; Cong N; Shi C; Bu W; Song J; Chen H
Hepatogastroenterology; 2014 Jun; 61(132):954-7. PubMed ID: 26158148
[TBL] [Abstract][Full Text] [Related]
18. Docetexal plus S-1 versus oxaliplatin plus S-1 for first-line treatment of patients with advanced gastric cancer: a retrospective study.
Wang M; Wu M; Wang W; Wang Q; Wang Y
Oncol Res Treat; 2014; 37(1-2):24-8. PubMed ID: 24613905
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
Pan T; Li XS; Xie QK; Wang JP; Li W; Wu PH; Zhao M
Clin Radiol; 2014 Dec; 69(12):e553-61. PubMed ID: 25304928
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture.
Zheng SZ; Liu DJ; Sun P; Yu GS; Xu YT; Gong W; Liu J
World J Gastroenterol; 2014 Nov; 20(43):16275-81. PubMed ID: 25473183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
